Stage II nonseminomatous germ-cell testicular tumors - the Indiana experience and risk-benefit analysis

Richard Foster, Richard Bihrle, J. S. Little, R. G. Rowland, J. P. Donohue

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Controversy exists in the appropriate management of patients with nonseminomatous testicular cancer presenting as clinical stage B disease. Traditional treatment in the United States has included retroperitoneal lymph-node dissection (RPLND). Conversely, in Europe and other places some of these patients have been managed with primary chemotherapy. The experience with RPLND in clinical stage B disease at Indiana University from 1965 to 1989 was reviewed. A total of 174 patients were considered to be in clinical stage B prior to RPLND. After RPLND, 23% of these patients (n=41) were found to have pathological stage A disease. In all, 77% (n=133) were determined to be in pathological stage B. Of those pathological stage B patients who did not receive adjuvant chemotherapy, 65% were cured by RPLND alone. The pathological stage B patients who went on the receive postoperative adjuvant chemotherapy displayed an overall 14% chance of relapse. (Patients treated early in the series did not receive cisplatin-based chemotherapy.) The overall survival over the entire period was 96%. In the more modern era, during which cisplatin-based chemotherapy was available, the overall survival was 98%. RPLND is an effective procedure for the management of clinical stage B nonseminomatous testicular cancer. It provides excellent survival in patients found to have pathological stage B disease; additionally, it avoids the unnecessary toxicity of chemotherapy in the 23% of patients who in fact are in pathological stage A.

Original languageEnglish
Pages (from-to)143-146
Number of pages4
JournalWorld Journal of Urology
Volume12
Issue number3
DOIs
StatePublished - Jun 1994

Fingerprint

Lymph Node Excision
Drug Therapy
Testicular Neoplasms
Adjuvant Chemotherapy
Cisplatin
Survival
Nonseminomatous germ cell tumor
Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Stage II nonseminomatous germ-cell testicular tumors - the Indiana experience and risk-benefit analysis. / Foster, Richard; Bihrle, Richard; Little, J. S.; Rowland, R. G.; Donohue, J. P.

In: World Journal of Urology, Vol. 12, No. 3, 06.1994, p. 143-146.

Research output: Contribution to journalArticle

@article{640adbe8da3543ea9c46b91a3dabe6e7,
title = "Stage II nonseminomatous germ-cell testicular tumors - the Indiana experience and risk-benefit analysis",
abstract = "Controversy exists in the appropriate management of patients with nonseminomatous testicular cancer presenting as clinical stage B disease. Traditional treatment in the United States has included retroperitoneal lymph-node dissection (RPLND). Conversely, in Europe and other places some of these patients have been managed with primary chemotherapy. The experience with RPLND in clinical stage B disease at Indiana University from 1965 to 1989 was reviewed. A total of 174 patients were considered to be in clinical stage B prior to RPLND. After RPLND, 23{\%} of these patients (n=41) were found to have pathological stage A disease. In all, 77{\%} (n=133) were determined to be in pathological stage B. Of those pathological stage B patients who did not receive adjuvant chemotherapy, 65{\%} were cured by RPLND alone. The pathological stage B patients who went on the receive postoperative adjuvant chemotherapy displayed an overall 14{\%} chance of relapse. (Patients treated early in the series did not receive cisplatin-based chemotherapy.) The overall survival over the entire period was 96{\%}. In the more modern era, during which cisplatin-based chemotherapy was available, the overall survival was 98{\%}. RPLND is an effective procedure for the management of clinical stage B nonseminomatous testicular cancer. It provides excellent survival in patients found to have pathological stage B disease; additionally, it avoids the unnecessary toxicity of chemotherapy in the 23{\%} of patients who in fact are in pathological stage A.",
author = "Richard Foster and Richard Bihrle and Little, {J. S.} and Rowland, {R. G.} and Donohue, {J. P.}",
year = "1994",
month = "6",
doi = "10.1007/BF00192274",
language = "English",
volume = "12",
pages = "143--146",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Stage II nonseminomatous germ-cell testicular tumors - the Indiana experience and risk-benefit analysis

AU - Foster, Richard

AU - Bihrle, Richard

AU - Little, J. S.

AU - Rowland, R. G.

AU - Donohue, J. P.

PY - 1994/6

Y1 - 1994/6

N2 - Controversy exists in the appropriate management of patients with nonseminomatous testicular cancer presenting as clinical stage B disease. Traditional treatment in the United States has included retroperitoneal lymph-node dissection (RPLND). Conversely, in Europe and other places some of these patients have been managed with primary chemotherapy. The experience with RPLND in clinical stage B disease at Indiana University from 1965 to 1989 was reviewed. A total of 174 patients were considered to be in clinical stage B prior to RPLND. After RPLND, 23% of these patients (n=41) were found to have pathological stage A disease. In all, 77% (n=133) were determined to be in pathological stage B. Of those pathological stage B patients who did not receive adjuvant chemotherapy, 65% were cured by RPLND alone. The pathological stage B patients who went on the receive postoperative adjuvant chemotherapy displayed an overall 14% chance of relapse. (Patients treated early in the series did not receive cisplatin-based chemotherapy.) The overall survival over the entire period was 96%. In the more modern era, during which cisplatin-based chemotherapy was available, the overall survival was 98%. RPLND is an effective procedure for the management of clinical stage B nonseminomatous testicular cancer. It provides excellent survival in patients found to have pathological stage B disease; additionally, it avoids the unnecessary toxicity of chemotherapy in the 23% of patients who in fact are in pathological stage A.

AB - Controversy exists in the appropriate management of patients with nonseminomatous testicular cancer presenting as clinical stage B disease. Traditional treatment in the United States has included retroperitoneal lymph-node dissection (RPLND). Conversely, in Europe and other places some of these patients have been managed with primary chemotherapy. The experience with RPLND in clinical stage B disease at Indiana University from 1965 to 1989 was reviewed. A total of 174 patients were considered to be in clinical stage B prior to RPLND. After RPLND, 23% of these patients (n=41) were found to have pathological stage A disease. In all, 77% (n=133) were determined to be in pathological stage B. Of those pathological stage B patients who did not receive adjuvant chemotherapy, 65% were cured by RPLND alone. The pathological stage B patients who went on the receive postoperative adjuvant chemotherapy displayed an overall 14% chance of relapse. (Patients treated early in the series did not receive cisplatin-based chemotherapy.) The overall survival over the entire period was 96%. In the more modern era, during which cisplatin-based chemotherapy was available, the overall survival was 98%. RPLND is an effective procedure for the management of clinical stage B nonseminomatous testicular cancer. It provides excellent survival in patients found to have pathological stage B disease; additionally, it avoids the unnecessary toxicity of chemotherapy in the 23% of patients who in fact are in pathological stage A.

UR - http://www.scopus.com/inward/record.url?scp=0028187666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028187666&partnerID=8YFLogxK

U2 - 10.1007/BF00192274

DO - 10.1007/BF00192274

M3 - Article

VL - 12

SP - 143

EP - 146

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -